Navigation Links
PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
Date:6/8/2009

nts on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

This press release contains forward-looking statements, including regarding PDL's expectations with respect to its 2009 royalty revenues.

Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
  • The ability to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
  • Changes in any of the other assumptions including foreign currency exchange rates on which PDL's projected royalty revenues are based;
  • The outcome of pending litigation or disputes; and
  • The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's fil
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 BioMedomics, Inc. ... ultra-sensitive POC diagnostic platforms and novel disease specific POC tests, ... of financing netting a total of $690,000. The investment is ... in the company. This group of private investors has significant ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... NEW DELHI, India, July 17 Following ... the stock market, Daiichi Sankyo,Company, Limited (TSE: ... Ranbaxy/500359) ("Ranbaxy") reiterate that the agreement,between Daiichi ... largest,controlling shareholders of Ranbaxy, is binding and ...
... the efforts of two kinds of bacteria to produce hydrogen ... for the other. According to an article in the August ... added bonus: leftover enzymes can be used to scavenge precious ... that convert hydrogen into energy. , Hydrogen has three times ...
... July 16 US Oncology Holdings, Inc. and ... second quarter,financial results on Thursday, August 7, 2008., ... been scheduled at 11:00,a.m., EDT, for the company,s ... this call, representatives of US Oncology,s management,team will ...
Cached Biology Technology:Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2Fuel from food waste: bacteria provide power 2
(Date:7/9/2014)... puzzle behind nature,s ability to split the water ... development of artificial photosynthesis for clean, green and ... collaboration of scientists led by researchers with the ... SLAC National Accelerator Laboratory. , Working at ... most powerful x-ray laser, the researchers were able ...
(Date:7/9/2014)... increasing concern about the prevalence of antibiotic-resistant illness, ... new pathway to disabling disease: blocking bacteria,s access ... showed how bacterial siderophore, a small molecule, captures ... bacterial growth as well as how the ... process. Their findings appear in a recent edition ...
(Date:7/9/2014)... first-ever global census of Adlie penguins shows that ... 53 percent larger than previously estimated. Adlie penguins ... to monitor and understand the effects of climate ... By using high-resolution satellite imagery, researchers from Stony ... a new method that permits regular monitoring of ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... WEST LAFAYETTE, Ind. - A Purdue University scientist has found ... unfavorable conditions, a finding he believes could one day be ... environments. David Salt, a professor of horticulture, noticed several ... thaliana that could tolerate higher levels of sodium had come ...
... 31, 2011A compact, self-contained, automated system for surveillance and ... deadly infectious diseases is a step closer to reality, ... the University of California Los Angeles School of Public ... from LANL and the UCLA School of Public Health ...
... and Torosaurus have long been considered the ... the giants, family tree further back in time, when a ... more well-known descendants, making it the earliest known member of ... after the Greek myth of the Titans, rivaled ...
Cached Biology News:Plants can adapt genetically to survive harsh environments 2LANL to certify automated influenza surveillance system 2LANL to certify automated influenza surveillance system 3Newly discovered dinosaur likely father of Triceratops 2
... numbers of samples may be carried out using ... minimum operator attention. System control and data ... CE 4900. The elegant, powerful and very ... and Windows 98 and 2000., The supplied automatic ...
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
Biology Products: